NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:NAVA - NO0010205966 - Common Stock
22.2 NOK
+0.4 (+1.83%)
Taking everything into account, NAVA scores 2 out of 10 in our fundamental rating. NAVA was compared to 54 industry peers in the Pharmaceuticals industry. NAVA may be in some trouble as it scores bad on both profitability and health. NAVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year NAVA has reported negative net income.
- NAVA had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: NAVA reported negative net income in multiple years.
- In multiple years NAVA reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a Return On Assets value of -5.53%, NAVA is not doing good in the industry: 70.37% of the companies in the same industry are doing better.
- With a Return On Equity value of -18.80%, NAVA is not doing good in the industry: 74.07% of the companies in the same industry are doing better.
- With a Return On Invested Capital value of 2.25%, NAVA is not doing good in the industry: 62.96% of the companies in the same industry are doing better.
- The Average Return On Invested Capital over the past 3 years for NAVA is below the industry average of 13.93%.
- The 3 year average ROIC (10.14%) for NAVA is well above the current ROIC(2.25%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -18.8% | ||
| ROIC | 2.25% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
- NAVA has a Operating Margin of 2.99%. This is in the lower half of the industry: NAVA underperforms 68.52% of its industry peers.
- In the last couple of years the Operating Margin of NAVA has grown nicely.
- NAVA has a Gross Margin of 37.32%. This is in the lower half of the industry: NAVA underperforms 77.78% of its industry peers.
- NAVA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.99% | ||
| PM (TTM) | N/A | ||
| GM | 37.32% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
- NAVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- NAVA has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, NAVA has more shares outstanding
- NAVA has a better debt/assets ratio than last year.
2.2 Solvency
- NAVA has a debt to FCF ratio of 27.52. This is a negative value and a sign of low solvency as NAVA would need 27.52 years to pay back of all of its debts.
- NAVA's Debt to FCF ratio of 27.52 is on the low side compared to the rest of the industry. NAVA is outperformed by 64.81% of its industry peers.
- NAVA has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- NAVA has a worse Debt to Equity ratio (1.34) than 72.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 27.52 | ||
| Altman-Z | N/A |
ROIC/WACC0.28
WACC7.96%
2.3 Liquidity
- A Current Ratio of 1.49 indicates that NAVA should not have too much problems paying its short term obligations.
- NAVA's Current ratio of 1.49 is in line compared to the rest of the industry. NAVA outperforms 57.41% of its industry peers.
- NAVA has a Quick Ratio of 1.49. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
- NAVA has a worse Quick ratio (0.77) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.49 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
- The earnings per share for NAVA have decreased strongly by -290.46% in the last year.
- Looking at the last year, NAVA shows a small growth in Revenue. The Revenue has grown by 2.64% in the last year.
- Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-290.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-194.12%
Revenue 1Y (TTM)2.64%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%12.89%
3.2 Future
- The Earnings Per Share is expected to grow by 31.39% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 12.79% on average over the next years. This is quite good.
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- NAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 30.23, the valuation of NAVA can be described as expensive.
- 64.81% of the companies in the same industry are cheaper than NAVA, based on the Price/Forward Earnings ratio.
- NAVA is valuated rather expensively when we compare the Price/Forward Earnings ratio to 24.30, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.23 |
4.2 Price Multiples
- NAVA's Enterprise Value to EBITDA ratio is in line with the industry average.
- NAVA's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47 | ||
| EV/EBITDA | 13.58 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
5. Dividend
5.1 Amount
- No dividends for NAVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OSL:NAVA (1/22/2026, 10:11:01 AM)
22.2
+0.4 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)N/A N/A
Inst Owners30.47%
Inst Owner ChangeN/A
Ins Owners12.02%
Ins Owner ChangeN/A
Market Cap532.36M
Revenue(TTM)539.42M
Net Income(TTM)-39.43M
Analysts82.86
Price Target36.72 (65.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.04%
Min Revenue beat(2)-7.18%
Max Revenue beat(2)-4.89%
Revenue beat(4)0
Avg Revenue beat(4)-4.82%
Min Revenue beat(4)-7.18%
Max Revenue beat(4)-1.92%
Revenue beat(8)1
Avg Revenue beat(8)-6.44%
Revenue beat(12)4
Avg Revenue beat(12)-1.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.23 | ||
| P/S | 0.99 | ||
| P/FCF | 47 | ||
| P/OCF | 36.33 | ||
| P/B | 2.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.58 |
EPS(TTM)-2.21
EYN/A
EPS(NY)0.73
Fwd EY3.31%
FCF(TTM)0.47
FCFY2.13%
OCF(TTM)0.61
OCFY2.75%
SpS22.49
BVpS8.74
TBVpS-10.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.53% | ||
| ROE | -18.8% | ||
| ROCE | 2.92% | ||
| ROIC | 2.25% | ||
| ROICexc | 2.52% | ||
| ROICexgc | 42.03% | ||
| OM | 2.99% | ||
| PM (TTM) | N/A | ||
| GM | 37.32% | ||
| FCFM | 2.1% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexgc growth 3Y90.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score2
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 27.52 | ||
| Debt/EBITDA | 4.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 25.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.49 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | N/A |
F-Score2
WACC7.96%
ROIC/WACC0.28
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-290.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-194.12%
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue 1Y (TTM)2.64%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%12.89%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%
EBIT growth 1Y-59.15%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year15.84%
EBIT Next 3Y37.82%
EBIT Next 5Y26.96%
FCF growth 1Y-75.72%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y-69.13%
OCF growth 3YN/A
OCF growth 5Y25.36%
NAVAMEDIC / NAVA.OL FAQ
Can you provide the ChartMill fundamental rating for NAVAMEDIC?
ChartMill assigns a fundamental rating of 2 / 10 to NAVA.OL.
Can you provide the valuation status for NAVAMEDIC?
ChartMill assigns a valuation rating of 1 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Overvalued.
What is the profitability of NAVA stock?
NAVAMEDIC (NAVA.OL) has a profitability rating of 2 / 10.